Unlocking value by interrogating pharma spending – RxBenefits
Pharmacy spend is becoming a key value lever at US portfolio companies as PE firms up their focus on healthcare oversight, says RxBenefits’ Peter Lombardi.
18 November 2024•5 mins read
Pharmacy spend is becoming a key value lever at US portfolio companies as PE firms up their focus on healthcare oversight, says RxBenefits’ Peter Lombardi.
Metal on how PE managers can lay the data foundations
17 October 2026 · 5 mins read
Why financial services dealmaking demands deep sector expertise
16 June 2026 · 10 mins read
Juniper Square on going from outputs to outcomes with AI
6 May 2026 · 5 mins read
Dealmaking: Is a rebound around the corner?
19 November 2025 · 10 mins read
Baker McKenzie’s Erika Lopez: Momentum shifts as PE embraces progress
31 March 2025 · 7 mins read
Bridge Bank: Stable banks enable tech companies to thrive in volatile markets
26 June 2023 · 5 mins read
How cyber-risk is reshaping private equity
3 April 2023 · 6 mins read
